Popular international healthcare journal Insights Care is pleased to feature Altasciences, spearheaded by Steve Mason, the distinguished Co-Chief Operating Officer, stands out for its commitment to seamless integration and transformative solutions.
Altasciences is a dedicated CRO/CDMO with a completely integrated solution providing pharma and biotech firms with an end-to-end early-stage drug development solution from lead candidate selection right on through to clinical proof of concept and beyond. With nine facilities in the U.S. and Canada, and a U.K.-based office, Altasciences provides a flexible and well-proven solution, and the full complement of CRO support services, to preclinical and clinical pharmacology studies like bioanalysis, formulation, manufacturing, and analytical services.
Standing out from the rest is the dedication in the core of Altasciences’ mission, which is breaking down barriers that are hindering the movement of critical information and insights between research and development, ultimately leading to faster delivery of life-saving treatments to those who need them.
With nearly three decades of experience in building preclinical businesses to their credit, the leadership of Steve enables all of Altasciences’ preclinical services and facilities to harmonize with all departments smoothly. At Altasciences, they remove safely the bottlenecks and gatekeepers that stand between the smooth and efficient flow of data. Steve and his teams simply remove the inefficiencies so the sponsors can get better drugs to the individuals who need them more quickly—that is always the ultimate goal.
Altasciences, shattered the CRO model and has provided them with a long-awaited alternative to outsourcing early-stage drug advancement, with a solution to overcome and diminish obstacles presented by the traditional paradigm. There had been a bundled idea for decades of industry talk, but Altasciences had vision, personnel, and focus to make it happen. Operating as an integrated preclinical through to clinical CRO/CDMO, the firm has the ability to safely accelerate a client’s drug to progress through stages of development. One of their strategic goals has been to sign up one of their latest preclinical recruits to specialize in late discovery and PK, with gene therapy, antibody, and cell-based treatments completing our biologics’ offering. They believe that the future growth of Altasciences can be maximized by involving its clients earlier in the drug development process, prior to regulatory studies, with a view of partnering with them throughout their entire early-stage development phase.
